Patents Assigned to The National Blood Authority
-
Patent number: 7118741Abstract: There is disclosed a synthetic cross-linker protein capable of binding a molecule or macromolecular species to a transcytosis receptor for transport of the molecule or macromolecule species across a mucous membrane, said cross-linker protein comprising a first binding region capable of binding selectively to a site on the said molecule or macromolecular species to be transported and a second binding region capable of binding selectively to a site on said receptor, wherein the first binding region is the antigen-binding site of a first antibody molecule having specificity for an antigenic site on said molecule or macromolecular species to be transported and the second binding region is the antigen-binding site of a second antibody molecule which has specificity for an antigenic site on the said transcytosis receptor.Type: GrantFiled: May 13, 1996Date of Patent: October 10, 2006Assignee: The National Blood AuthorityInventors: Jacqueline Elizabeth Mary Gilmour, David Joseph Unsworth
-
Patent number: 6992061Abstract: The invention relates to a method of removing endotoxin from preparation of alpha-1-acid glycoprotein (orosomucoid) by contact with a finely divided non-toxic resin such as fumed silica. The invention also relates to a purification process for alpha-1-acid glycoprotein which includes this depyrogenation step, and to the depyrogenated product and its clinical uses.Type: GrantFiled: February 26, 2002Date of Patent: January 31, 2006Assignee: National Blood AuthorityInventors: John Edward More, Jacqueline Rott, David Roger Lewin
-
Publication number: 20020128180Abstract: The invention relates to a method of removing endotoxin from preparation of alpha-1-acid glycoprotein (orosomucoid) by contact with a finely divided non-toxic resin such as fumed silica. The invention also relates to a purification process for alpha-1-acid glycoprotein which includes this depyrogenation step, and to the depyrogenated product and its clinical uses.Type: ApplicationFiled: February 26, 2002Publication date: September 12, 2002Applicant: National Blood AuthorityInventors: John Edward More, Jacqueline Rott, David Roger Lewin
-
Patent number: 6387877Abstract: The invention relates to a method of removing endotoxin from preparations of alpha-1-acid glycoprotein (orosomucoid) by contact with a finely divided non-toxic resin such as fumed silica. The invention also relates to a purification process for alpha-1-acid glycoprotein which includes this deprogenation step, and to the depyrogenated product and its clinical uses.Type: GrantFiled: January 25, 1999Date of Patent: May 14, 2002Assignee: National Blood AuthorityInventors: John Edward More, Jacqueline Rott, David Roger Lewin
-
Patent number: 5919910Abstract: The present invention provides DNA sequences encoding complementarity determining regions of variable domains of human anti-RhD antibodies and their use in the production of recombinant chimeric antibody molecules. Chimeric antibody molecules against the Rhesus (D) antigen or an antigen binding fragment thereof, as well as anti-Rhesus (D) reagents and pharmaceutical compositions comprising said chimeric antibodies are also provided.Type: GrantFiled: June 7, 1995Date of Patent: July 6, 1999Assignee: National Blood AuthorityInventor: Nevin Campbell Hughes-Jones
-
Patent number: 5831063Abstract: The present invention provides DNA sequences encoding complementarity determining regions of variable domains of human anti-RhD antibodies and their use in the production of recombinant chimaeric antibody molecules.Type: GrantFiled: June 23, 1992Date of Patent: November 3, 1998Assignee: National Blood AuthorityInventor: Nevin Campbell Hughes-Jones
-
Patent number: 5773222Abstract: A solid phase method of detection or assay of the presence or amount in a serum or plasma sample of a target antibody specific to a cell surface antigen. The sample is contacted with an immobilised preparation of cells bearing the antigen and antibody bound thereto is detected or assayed by means of an indicator comprising a binding partner for the antibody bound to labelled latex particles.Type: GrantFiled: January 11, 1995Date of Patent: June 30, 1998Assignee: National Blood AuthorityInventor: Marion Lesley Scott
-
Patent number: 5665356Abstract: The present invention provides human monoclonal antibodies having the following essential characteristics: (a) binding to Rh(D) antigen, but not C, c, E or e antigens of the Rh blood group system; (b) being IgG1 proteins; (c) having kappa light chains; (d) being Glm(3) or Glm(1,17) allotype; (e) binding to D.sup.u cells by an indirect antiglobulin test; (f) binding to D.sup.IV, D.sup.V and D.sup.VII variant antigens; and (g) not binding to D.sup.VI or D.sup.B variant antigens, which may be employed for Rh-typing of red blood cells and passive immunization to prevent hemolytic disease of the newborn. Such a monoclonal antibody is exemplified by the monoclonal antibodies of cell lines ECACC 87091605 and 87091604 deposited at the European Collection of Animal Cell Cultures, Public Health Laboratory Service Center for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire, SP4, OJG, England on Sep. 16, 1987.Type: GrantFiled: June 7, 1995Date of Patent: September 9, 1997Assignee: The National Blood AuthorityInventors: Benjamin Arthur De Burgh Bradley, Alan Doyle, Belinda Mary Kumpel
-
Patent number: 5653978Abstract: The present invention provides human monoclonal antibodies having the following essential characteristics: (a) binding to Rh(D) antigen, but not C, c, E or e antigens of the Rh blood group system; (b) being IgG3 proteins; (c) having kappa light chains; (d) being of the allotype G3m(21); (e) binding to D.sup.u cells by an indirect antiglobulin test; (f) binding to D.sup.IV, D.sup.V and D.sup.VII variant antigens; and (g) not binding to D.sup.VI or D.sup.B variant antigens, which may be employed for Rh-typing of red blood cells and passive immunization to prevent hemolytic disease of the newborn. Such a monoclonal antibody is exemplified by the monoclonal antibody of cell line ECACC 87091606 deposited at the European Collection of Animal Cell Cultures, Public Health Laboratory Service Center for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire, SP4, OJG, England, on Sep. 16, 1987.Type: GrantFiled: June 6, 1995Date of Patent: August 5, 1997Assignee: The National Blood AuthorityInventors: Benjamin Arthur De Burgh Bradley, Alan Doyle, Belinda Mary Kumpel
-
Patent number: 5496548Abstract: The present invention provides human monoclonal antibodies having the following essential characteristics: (a) binding to Rh(D) antigen, but not C, c, E or e antigens of the Rh blood group system; (b) being IgG3 proteins; (c) having kappa light chains; (d) being of the allotype G3m(21); (e) binding to D.sup.u cells by an indirect antiglobulin test; (f) binding to D.sup.IV, D.sup.V and D.sup.VII variant antigens; and (g) not binding to D.sup.VI or D.sup.B variant antigens, which may be employed for Rh-typing of red blood cells and passive immunization to prevent hemolytic disease of the newborn. Such a monoclonal antibody is exemplified by the monoclonal antibody of cell line ECACC 87091606 deposited at the European Collection of Animal Cell Cultures, Public Health Laboratory Service Center for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire, SP4, OJG, England of Sep. 16, 1987.Type: GrantFiled: April 13, 1993Date of Patent: March 5, 1996Assignee: National Blood AuthorityInventors: Benjamin A. De Burgh, Alan Doyle, Belinda M. Kumpel
-
Patent number: 5487891Abstract: The present invention provides human monoclonal antibodies having the following essential characteristics: (a) binding to Rh(D) antigen, but not C, c, E or e antigens of the Rh blood group system; (b) being IgGl proteins; (c) having kappa light chains; (d) being Glm(3) or Glm(1,17) allotype; (e) binding to D.sup.u cells by an indirect antiglobulin test; (f) binding to D.sup.IV, D.sup.V and D.sup.VII variant antigens; and (g) not binding to D.sup.VI or D.sup.B variant antigens, which may be employed for Rh-typing of red blood cells and passive immunization to prevent hemolytic disease of the newborn. Such a monoclonal antibody is exemplified by the monoclonal antibodies of cell lines ECACC 87091605 and 87091604 deposited at the European Collection of Animal Cell Cultures, Public Health Laboratory Service Center for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire, SP4, OJG, England on 16th September 1987.Type: GrantFiled: May 6, 1993Date of Patent: January 30, 1996Assignee: National Blood AuthorityInventors: Benjamin A. D. B. Bradley, Alan Doyle, Belinda M. Kumpel
-
Patent number: 5445958Abstract: A method for at least partially separating vitamin K-dependent blood clotting factors from a mixture containing at least one such factor, e.g. a prothrombin complex concentrate, which comprises adsorption of said mixture on to a chelate of a polyvalent metal immobilized on an inert support, e.g. Cu.sup.2 + -primed Chelating Sepharose, followed by elution to yield one or more fractions enriched in respect of one of said factors.Type: GrantFiled: February 23, 1993Date of Patent: August 29, 1995Assignee: National Blood AuthorityInventor: Peter A. Feldman